OTLK

Outlook TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 20.8 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.1.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-21

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-21 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-21

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $8.00

Why

Momentum21 · Δ7d -

Value41 · Δ7d +0.1

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

-0.0

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 20.8 / Value 41.1

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$227.41M

Beta

0.14

Shares Out

160.15M

P/E (TTM) · Derived

-0.8

P/S (TTM)

23.11

P/FCF (TTM) · Derived

-0.95

Rev YoY

-100.0%

EPS YoY

-96.4%

Gross Margin

+70.8%

Op Margin

-4455.0%

Net Debt

$22.11M

Current Ratio

0.54

As of 2026-07-21 • Updated nightlySource: Internal modelMethodology